Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Cyclopentanohydrophenanthrene ring system doai
Reexamination Certificate
2005-05-31
2005-05-31
Badio, Barbara P. (Department: 1616)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Cyclopentanohydrophenanthrene ring system doai
C514S176000, C514S177000, C514S182000, C514S841000, C540S107000, C552S556000, C552S595000, C552S598000, C552S602000, C552S608000
Reexamination Certificate
active
06900193
ABSTRACT:
The present invention relates, inter alia, to compounds having the general formula:in which: R1is a member selected from the group consisting of —OCH3, —SCH3, —N(CH3)2, —NHCH3, —NC4H8, —NC5H10, —NC4H8O, —CHO, —CH(OH)CH3, —C(O)CH3, —O(CH2)2N(CH3)2, and —O(CH2)2NC5H10; R2is a member selected from the group consisting of hydrogen, halogen, alkyl, acyl, hydroxy, alkoxy (e.g., methoxy, ethoxy, vinyloxy, ethynyloxy, cyclopropyloxy, etc.), acyloxy (e.g., acetoxy, glycinate, etc.), alkylcarbonate, cypionyloxy, S-alkyl, —SCN, S-acyl and —OC(O)R6, wherein R6is a functional group including, but not limited to, alkyl (e.g., methyl, ethyl, etc.), alkoxy ester (e.g., —CH2OCH3) and alkoxy (—OCH3); R3is a member selected from the group consisting of alkyl, hydroxy, alkoxy and acyloxy; R4is a member selected from the group consisting of hydrogen and alkyl; and X is a member selected from the group consisting of ═O and ═N—OR5, wherein R5is a member selected from the group consisting of hydrogen and alkyl.In addition to providing the compounds of Formula I, the present invention provides methods wherein the compounds of Formula I are advantageously used, inter alia, to antagonize endogenous progesterone; to induce menses; to treat endometriosis; to treat dysmenorrhea; to treat endocrine hormone-dependent tumors; to treat meningiomas; to treat uterine leiomyomas; to treat uterine fibroids; to inhibit uterine endometrial proliferation; to induce cervical ripening; to induce labor; and for contraception.
REFERENCES:
patent: 5073548 (1991-12-01), Cook et al.
patent: 5244886 (1993-09-01), Scholz et al.
patent: 5741787 (1998-04-01), Peeters
patent: 0129499 (1984-06-01), None
Acosta et al., “Oxidative Demethylation of 4-Substituted N,N-Dimethylanilines with Iodine and Calcium Oxide in the Presence of Methanol.”, J. Chem. Soc., Chem. Commun., (17), pp. 1985-1986, 1994.
Acosta Carmie K.
Blye Richard P.
Cessac James W.
Kim Hyun K.
Rao Pemmaraju N.
Badio Barbara P.
The United States of America as represented by the Department of
Townsend & Townsend & Crew LLP
LandOfFree
Structural modification of 19-norprogesterone I:... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Structural modification of 19-norprogesterone I:..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Structural modification of 19-norprogesterone I:... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3427293